HK Stock Market Move | ASCLETIS-B (01672) rose more than 5% in the morning, demonstrating significant competitive advantage with ASC30. Institutions stated that it has great potential in the field of biopharmaceutical research and development.

ASCLETIS-B (01672) rose by over 5% in the morning, reaching an increase of 5.12% as of the time of writing, closing at 13.56 Hong Kong dollars, with a trading volume of 13.2847 million Hong Kong dollars. On the news front, Gilead Sciences had previously announced positive data from the Phase IIa study of its oral GLP-1 drug ASC30 for the treatment of obesity. Citigroup released a research report stating that these data further demonstrate the potential of ASC30 as best in class and enhance confidence in future collaborations. It is expected that the stock price will have a positive reaction; the "buy/high risk" rating is reiterated with a target price of 32 Hong Kong dollars. Orient, on the other hand, stated that the weight loss data for ASC30 is superior, with good safety profile, and the molecular patent has already been granted in the United States, with significant potential in the BD market. In addition, Gilead has developed an ASC30 subcutaneous injection formulation for weight loss and maintenance therapy based on the Ultra-Long Acting Drug Development Platform (ULAP), with apparent half-lives of 46 days and 75 days respectively, far exceeding other ultra-long acting GLP-1 drugs, while maintaining a favorable safety profile.